Metsera Inc
MTSR26.650USD
-2.660-9.08%
Cierre 06/25, 16:00（ET）Cotizaciones retrasadas 15 min
2.79BCap. mercado
PérdidaP/E TTM
Más Datos de Metsera Inc Compañía
Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The Company's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
Información de la empresa
Símbolo de cotizaciónMTSR
Nombre de la empresaMetsera Inc
Fecha de salida a bolsaJan 31, 2025
Fundada en2022
Director ejecutivoMr. Christopher Whitten Bernard
Número de empleados74
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección3 World Trade Center
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10007
Teléfono12127846595
Sitio Webhttps://metsera.com/
Símbolo de cotizaciónMTSR
Fecha de salida a bolsaJan 31, 2025
Fundada en2022
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul L. Berns
Mr. Paul L. Berns
Independent Director
Independent Director
957.56K
--
Mr. Matthew Lang, J.D.
Mr. Matthew Lang, J.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Dr. Brian Hubbard, Ph.D.
Dr. Brian Hubbard, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Steven Marso, M.D.
Dr. Steven Marso, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
Independent Director
Independent Director
--
--
Dr. Clive A. Meanwell, M.D.
Dr. Clive A. Meanwell, M.D.
Executive Chairman of the Board, Founder
Executive Chairman of the Board, Founder
--
--
Mr. Christopher Whitten Bernard
Mr. Christopher Whitten Bernard
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher J. (Chris) Visioli
Mr. Christopher J. (Chris) Visioli
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul L. Berns
Mr. Paul L. Berns
Independent Director
Independent Director
957.56K
--
Mr. Matthew Lang, J.D.
Mr. Matthew Lang, J.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Dr. Brian Hubbard, Ph.D.
Dr. Brian Hubbard, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Steven Marso, M.D.
Dr. Steven Marso, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
ARCH Venture Partners
25.53%
Fidelity Management & Research Company LLC
14.44%
Validae Health, L.P
12.15%
Alphabet, Inc.
4.72%
MIC Capital Management UK LLP
4.32%
Other
38.84%
Accionistas
Accionistas
Proporción
ARCH Venture Partners
25.53%
Fidelity Management & Research Company LLC
14.44%
Validae Health, L.P
12.15%
Alphabet, Inc.
4.72%
MIC Capital Management UK LLP
4.32%
Other
38.84%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
36.12%
Investment Advisor
25.35%
Corporation
12.15%
Investment Advisor/Hedge Fund
11.64%
Hedge Fund
4.53%
Individual Investor
0.91%
Research Firm
0.08%
Bank and Trust
0.02%
Other
9.20%
Participación institucional
Actualizado: mar., 4 de mar
Actualizado: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
22
61.21M
58.27%
+60.25M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
ARCH Venture Partners
26.82M
25.53%
+26.82M
--
Feb 03, 2025
Fidelity Management & Research Company LLC
11.06M
10.53%
+11.06M
--
Feb 03, 2025
Wellington Management Company, LLP
1.86M
1.77%
+1.86M
--
Jan 30, 2025
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
Roundhill GLP-1 & Weight Loss ETF
3.6%
iShares Health Innovation Active ETF
0.11%
Proshares Ultra Russell 2000
0.02%
iShares Russell 2000 ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
ProShares UltraPro Russell2000
0.02%
iShares Russell 2000 Value ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Schwab U.S. Broad Market ETF
0%
Roundhill GLP-1 & Weight Loss ETF
Proporción3.6%
iShares Health Innovation Active ETF
Proporción0.11%
Proshares Ultra Russell 2000
Proporción0.02%
iShares Russell 2000 ETF
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0.02%
ProShares UltraPro Russell2000
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.01%
Fidelity Nasdaq Composite Index ETF
Proporción0.01%
Schwab U.S. Small-Cap ETF
Proporción0.01%
Schwab U.S. Broad Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
